Microbiome Metabolic Pathways and Disease provides insight into the interaction of microbial metabolic pathways in the human body and the impact these can have on a variety of diseases. By analyzing these pathways the book seeks to investigate how these metabolic processes can be targeted and manipulated in order to treat various disorders and diseases. Topics covered in the book include microbial shikimate pathways, protein biosynthesis, tryptophan metabolites, microbiome metabolic engineering, fecal microbiota transplantation, and virulence factors. Additionally, a variety of conditions are covered, such as disorders associated with metabolic syndromes, serotonin syndromes, Alzheimer’s disease, and Covid-19, providing a detailed overview of how metabolic pathways of microbiome can impact health and disease in the human body.
1. Microbial Metabolism and Disease - p. Page i 2. Cover - p. Page i 3. Front Matter - p. Page ii 4. Table of Contents - p. Page iii 5. Copyright - p. Page iv 6. List of Illustrations - p. Page v 7. List of Tables - p. Page vi 8. Chapter 1 : Naturally occurring affectors of tRNA aminoacylation in transition from health to disease: interference in the initial step of protein biosynthesis - p. Page vi 9. Chapter 2 : Physicochemical, biochemical, and cell biology properties and byproducts of tryptamine and other “trace” amines - p. Page 22 10. Chapter 3 : Tryptophan metabolites and biogenic amines in physical exercises and metabolic syndrome - p. Page 31 11. Chapter 4 : Tryptamine in inflammation and regulation of gene transcription - p. Page 40 12. Chapter 5 : Genes encoding mammalian, plant, and microbial aromatic amino acid decarboxylase - p. Page 43 13. Chapter 6 : Decarboxylases producing tryptamine and other biogenic amines in the human microbiome - p. Page 59 14. Chapter 7 : Microbial shikimate pathway in diseases - p. Page 66 15. Chapter 8 : Biogenic amines in fasting, feeding, and stress conditions - p. Page 76 16. Chapter 9 : Metabolites of shikimate and tryptophan pathways in coronavirus disease (COVID-19) - p. Page 85 17. Chapter 10 : Virulence factors - p. Page 104 18. Chapter 11 : Relation of human gut Alzheimer disease associated sequence (ADAS) with shikimate pathway metabolites - p. Page 121 19. Chapter 12 : Benefits of using fecal microbiota transplantation (FMT) as treatment have been controversial - p. Page 135 20. Chapter 13 : Shikimate pathway enzymes in human microbiome. Putative gene candidates for gene knockout in diseases caused by infections - p. Page 144 21. Chapter 14 : Tryptophan biosynthesis pathway in human microbiome and disease - p. Page 156 22. Chapter 15 : Antibodies to tryptamine and other biogenic amines: potential usage for human diagnostics and immunotherapy - p. Page 174 23. Chapter 16 : Cell death in Alzheimer disease brain and tryptamine-treated cells: microscopy - p. Page 192 24. Chapter 17 : Microbial metabolism in etiology of neurodegenerative and related diseases - p. Page 213 25. Chapter 18 : Tryptamine produced by human microbiome as an inhibitor of microbial and mammalian enzymes and a ligand of receptors - p. Page 221 26. References - p. Page 241 27. Index - p. Page 241
Microbiome Metabolic Pathways and Disease provides insight into the interaction of microbial metabolic pathways in the human body and the impact these can have on a variety of diseases. By analyzing these pathways the book seeks to investigate how these metabolic processes can be targeted and manipulated in order to treat various disorders and diseases. Topics covered in the book include microbial shikimate pathways, protein biosynthesis, tryptophan metabolites, microbiome metabolic engineering, fecal microbiota transplantation, and virulence factors. Additionally, a variety of conditions are covered, such as disorders associated with metabolic syndromes, serotonin syndromes, Alzheimer’s disease, and Covid-19, providing a detailed overview of how metabolic pathways of microbiome can impact health and disease in the human body.
1. Microbial Metabolism and Disease - p. Page i 2. Cover - p. Page i 3. Front Matter - p. Page ii 4. Table of Contents - p. Page iii 5. Copyright - p. Page iv 6. List of Illustrations - p. Page v 7. List of Tables - p. Page vi 8. Chapter 1 : Naturally occurring affectors of tRNA aminoacylation in transition from health to disease: interference in the initial step of protein biosynthesis - p. Page vi 9. Chapter 2 : Physicochemical, biochemical, and cell biology properties and byproducts of tryptamine and other “trace” amines - p. Page 22 10. Chapter 3 : Tryptophan metabolites and biogenic amines in physical exercises and metabolic syndrome - p. Page 31 11. Chapter 4 : Tryptamine in inflammation and regulation of gene transcription - p. Page 40 12. Chapter 5 : Genes encoding mammalian, plant, and microbial aromatic amino acid decarboxylase - p. Page 43 13. Chapter 6 : Decarboxylases producing tryptamine and other biogenic amines in the human microbiome - p. Page 59 14. Chapter 7 : Microbial shikimate pathway in diseases - p. Page 66 15. Chapter 8 : Biogenic amines in fasting, feeding, and stress conditions - p. Page 76 16. Chapter 9 : Metabolites of shikimate and tryptophan pathways in coronavirus disease (COVID-19) - p. Page 85 17. Chapter 10 : Virulence factors - p. Page 104 18. Chapter 11 : Relation of human gut Alzheimer disease associated sequence (ADAS) with shikimate pathway metabolites - p. Page 121 19. Chapter 12 : Benefits of using fecal microbiota transplantation (FMT) as treatment have been controversial - p. Page 135 20. Chapter 13 : Shikimate pathway enzymes in human microbiome. Putative gene candidates for gene knockout in diseases caused by infections - p. Page 144 21. Chapter 14 : Tryptophan biosynthesis pathway in human microbiome and disease - p. Page 156 22. Chapter 15 : Antibodies to tryptamine and other biogenic amines: potential usage for human diagnostics and immunotherapy - p. Page 174 23. Chapter 16 : Cell death in Alzheimer disease brain and tryptamine-treated cells: microscopy - p. Page 192 24. Chapter 17 : Microbial metabolism in etiology of neurodegenerative and related diseases - p. Page 213 25. Chapter 18 : Tryptamine produced by human microbiome as an inhibitor of microbial and mammalian enzymes and a ligand of receptors - p. Page 221 26. References - p. Page 241 27. Index - p. Page 241
